综合的多omics分析确定了转激素受体作为食道癌症的治疗点
Xinhai Sun1, Yuanchang Zhu2, Yi Chen3
1Department of Thoracic Surgery, Fujian Institute of Thoracic and Cardiac Surgery, Fujian Medical University Union Hospital, Fuzhou, China; Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China.
International journal of biological macromolecules
|October 9, 2025
概括
转激素受体 (TFRC) 是一种用于食道癌 (ESCA) 的新生物标志物. 高TFRC表达与预后不佳和免疫逃避相关,表明TFRC是潜在的免疫治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 食道癌 (ESCA) 是一个重要的健康挑战,有效的生物标志物有限.
- 了解驱动ESCA进展和免疫逃避的分子机制对于开发新疗法至关重要.
研究的目的:
- 通过多omics方法识别食道癌 (ESCA) 的新生物标志物.
- 阐明已识别的生物标志物在ESCA进展和免疫逃避中的作用.
主要方法:
- 单细胞RNA测序和ESCA样本的转录组分析.
- 将基因表达量化特征位点 (eQTL) 分析与全基因组关联研究 (GWAS) 的整合.
- 多重复合免疫光测试以评估免疫细胞透和TFRC表达.
主要成果:
- 转移素受体 (TFRC) 被确定为与ESCA相关的关键基因.
- 增加TFRC表达与预后不佳,药物代谢改变和ESCA免疫细胞透减少有关.
- 高TFRC表达与免疫逃避,降低CD8+T细胞透和增加M2巨细胞透相关.
- 降低TFRC促进了M1巨细胞的两极分化,并增强了CD8+ T细胞的透.
结论:
- 在ESCA的发展和免疫逃生机制中,TFRC起着至关重要的作用.
- TFRC调节铁的可用性,影响瘤细胞的存活和活动.
- TFRC代表了食道癌免疫治疗的潜在治疗标.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Early Endosome: Endocytosis of Transferrin
4.7K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
4.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


